Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia

Fig. 2

Modulation of NK and T cell reactivity by the anti-CD3/CD16 parts of the BFP. NKG2D-CD3, NKG2D-CD16, NKG2D-Fc-ADCC were immobilized to plastic as described in the methods section. Then PBMC of healthy donors were incubated on the immobilized fusion proteins or control. a, b Expression of CD69 and CD25 as markers for early and intermediate activation, and CD107a as marker for degranulation were determined after 24 h, 48 h and 4 h, respectively, on (a) NK cells after counterstaining for CD56+CD3 or (b) T cells as identified by counterstaining for CD3, CD4 and CD8 by flow cytometry. Representative FACS plots of single experiments and combined data obtained with 8 different PBMC donors are shown (Mean ± SEM). c Supernatants of cultures were harvested after 4 h and IFN-γ levels were measured by ELISA (n = 10 different donors, Mean ± SEM)

Back to article page